SARS-CoV-2 Interstitial Pneumonia Treated With Tocilizumab in a Patient Affected by Classical Hodgkin Lymphoma

SARS-CoV-2 Interstitial Pneumonia Treated With Tocilizumab in a Patient Affected by Classical Hodgkin Lymphoma

Bibliografski detalji
Glavni autori:	Chiara Rusconi, Giulio Cassanello, Anna Guidetti, Chiara Oltolini, Vincenzo Marasco, Lucio Morabito, Matteo Della Porta, Rodolfo Lanocita, Gabriele Papagni, Cristiana Carniti, Paolo Corradini
Format:	Članak
Jezik:	English
Izdano:	Wiley 2020-10-01
Serija:	HemaSphere
Online pristup:	http://journals.lww.com/10.1097/HS9.0000000000000472

Slični predmeti

P105: Decisional role of interim PET in relapsed/refractory classical Hodgkin Lymphoma treated with four begev cycles
od: Chiara Rusconi, i dr.
Izdano: (2022-10-01)

P1070: DECISIONAL ROLE OF INTERIM PET IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA TREATED WITH BEGEV CHEMOTHERAPY AS FIRST SALVAGE
od: Chiara Rusconi, i dr.
Izdano: (2023-08-01)

P006: Clinical outcome of classical Hodgkin Lymphoma patients receiving systemic anti-lymphoma treatment during SARS-COV-2 positivity: Results from the chemo-covid study on behalf of fondazione italiana linfomi
od: Chiara Rusconi, i dr.
Izdano: (2022-10-01)

Safety of Tocilizumab on Rheumatoid Arthritis in Patients with Interstitial Lung Disease
od: Otsuji N, i dr.
Izdano: (2024-06-01)

Rapid Antibody Testing for SARS-CoV-2 in Asymptomatic and Paucisymptomatic Healthcare Professionals in Hematology and Oncology Units Identifies Undiagnosed Infections
od: Paolo Corradini, i dr.
Izdano: (2020-06-01)

Genetics of classical Hodgkin Lymphoma
od: Gianluca Schiavoni, i dr.
Izdano: (2018-06-01)

Journal Club: Efficacy of Tocilizumab in Early Systemic Sclerosis–Related Interstitial Lung Disease
od: Vivekanand Tiwari, i dr.
Izdano: (2022-02-01)

Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma
od: Paolo F. Caimi, i dr.
Izdano: (2021-10-01)

Immune checkpoint inhibitors in combination with radiotherapy as salvage treatment for relapsed/refractory classical Hodgkin lymphoma: A retrospective analysis in 12 patients
od: Elisa Lucchini, i dr.
Izdano: (2021-06-01)

Controversies in the Treatment of Classical Hodgkin Lymphoma
od: Dennis A. Eichenauer, i dr.
Izdano: (2018-10-01)

Classical Hodgkin’s Lymphoma Presenting as Erythroderma
od: Kumar Parimalam, i dr.
Izdano: (2022-11-01)

Tocilizumab modulates the activity of the classical and alternative complement pathways in rheumatoid arthritis patients
od: Iván Ferraz-Amaro, i dr.
Izdano: (2025-01-01)

The real risk of secondary non-Hodgkin lymphoma following classical Hodgkin lymphoma
od: Ahmet Dogan
Izdano: (2022-10-01)

Treatment outcomes in classic Hodgkin lymphoma: 5‐year update from the Brazilian Hodgkin Lymphoma Registry
od: Irene Biasoli, i dr.
Izdano: (2023-11-01)

P054: The Kinase CK2 is deregulated and targetable in classical Hodgkin Lymphoma
od: Andrea Visentin, i dr.
Izdano: (2022-10-01)

Evolution of drug therapy for classical Hodgkin lymphoma
od: N. Y. Samaneva, i dr.
Izdano: (2022-09-01)

CAR-T Cell Therapy for Classical Hodgkin Lymphoma
od: Mikalai Katsin, i dr.
Izdano: (2023-12-01)

Current directions in the treatment of classical Hodgkin lymphoma
od: Frank G. Keller, i dr.
Izdano: (2023-11-01)

Treatment Of Classical Hodgkin Lymphoma: The State Of The Art
od: Carmino Antonio de Souza, i dr.
Izdano: (2023-10-01)

Bone marrow involvement by classic Hodgkin lymphoma
od: Mohammad Barouqa, i dr.
Izdano: (2022-05-01)

Aberrant synaptophysin expression in classic Hodgkin lymphoma
od: Soyoung Im, i dr.
Izdano: (2022-11-01)

Bob-1 is expressed in classic Hodgkin lymphoma
od: Abd El All Howayda S
Izdano: (2007-03-01)

Relapsed and refractory classical Hodgkin lymphoma immunotherapy
od: Kirill Lepik
Izdano: (2020-10-01)

Composite follicular lymphoma and classic Hodgkin lymphoma
od: Han-Na Kim, i dr.
Izdano: (2022-01-01)

Update on tocilizumab in rheumatoid arthritis: a narrative review
od: Simone Parisi, i dr.
Izdano: (2025-02-01)

Accelerated subcutaneous nodulosis in patients with rheumatoid arthritis treated with tocilizumab: a case series
od: Rossella Talotta, i dr.
Izdano: (2018-06-01)

The Management of Classical Hodgkin's Lymphoma: Past, Present, and Future
od: S. E. Richardson, i dr.
Izdano: (2011-01-01)

Hemophagocytic Lymphohistiocytosis in a Patient with Classical Hodgkin Lymphoma
od: G. Hyun, i dr.
Izdano: (2016-01-01)

Classic Hodgkin lymphoma-nodular sclerosis – case report
od: Mihaela Lebedenco, i dr.
Izdano: (2023-06-01)

Optimization of the first line treatment in classical Hodgkin's lymphoma
od: Pauline Brice
Izdano: (2018-06-01)

Cell-Free DNA for the Management of Classical Hodgkin Lymphoma
od: Vincent Camus, i dr.
Izdano: (2021-03-01)

An updated portrait of monocyte-macrophages in classical Hodgkin lymphoma
od: Isacco Ferrarini, i dr.
Izdano: (2023-02-01)

The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma
od: Lai C, i dr.
Izdano: (2019-12-01)

Tocilizumab (Actemra)
od: Martin Sheppard, i dr.
Izdano: (2017-09-01)

P014 (0098) CD47 IS EXPRESSED ON HODGKIN REED STERNBERG CELLS IN CLASSICAL HODGKIN LYMPHOMA
Izdano: (2018-10-01)

Reed-Sternberg and Hodgkin cells in bone marrow aspirate from a classical Hodgkin lymphoma patient
od: Leonardo Rodrigues Oliveira, i dr.
Izdano: (2022-04-01)

P110: Outcome of high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT) as first salvage treatment for relapsed or refractory classical Hodgkin Lymphoma (cHL) in the era of PET-adapted strategy among Italian centers
od: Simonetta Viviani, i dr.
Izdano: (2022-10-01)

Classical Hodgkin Lymphoma Presenting with Severe, Recurrent Hypothermic Episodes
od: Jonas Juul Hansen, i dr.
Izdano: (2018-01-01)

Severe Aplastic Anemia as First Manifestation of Classical Hodgkin Lymphoma
od: Cláudia L. Pedrosa, i dr.
Izdano: (2021-01-01)

Cerebellar involvement in classical Hodgkin’s lymphoma: A case report
od: Suyash Chinchanikar, i dr.
Izdano: (2024-09-01)